IPD secures funding of €2.1M to initiate its first-in-human trials for prosthetic joint infections

PRESS RELEASE

Amsterdam, July 20, 2023

IPD B.V. (Implant Preservation Devices), a Netherlands-based start-up specializing in the treatment of prosthetic joint infections, raised €2.1 million in its seeding round, which closed on Friday July 14th 2023, contributing to the development of its first-in-human device for a clinical trial set to commence in early 2024.

IPD wants to thank their investors for their trust and confidence in this revolutionary innovation and team.

Founded in December 2020 by NLC The European Healthtech Venture Builder and Leiden University Medical Center, IPD is located in PLNT business centre in Leiden, the Netherlands. IPD is developing a medical device using non-contact induction heating technology to treat prosthetic joint and metal implant infections. By using induction technology, the implant is heated, while still inside the patient, eliminating bacteria on the implant and ultimately curing the infection. Prosthetic joint infection is a devastating and life-threatening complication, with over 250,000 patients worldwide. Laboratory studies show a significant positive impact, using non-contact induction technology, on the treatment of these infections. With a highly experienced team alongside the innovators, Prof. Dr. R. Nelissen and Asst. Prof. Dr. B. Pijls, IPD aims at a multicenter study in 2025 and market introduction early 2026.

Discover more about the challenge IPD seeks to address and the status of its novel medical device here.

 

About NLC

NLC is the leading European healthtech venture builder. NLC identifies top-notch early-stage healthcare inventions and brings them to market, acting as the connecting link between technology innovation and entrepreneurship in medtech, biotech and digital health. To optimize patient care and enhance its positive and sustainable impact, NLC collaborates with corporates such as Philips and healthcare and academic research institutions such as Oxford University and Mayo Clinic.

NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, 17. With its growing team of more than 80 professionals and over 110 portfolio ventures built across 11 European countries, NLC is currently expanding its impact-driven operations to the US and the Gulf region.

NLC Health Ventures Footer